BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 27
• 30
• 31

• Drug Development

  NOXXON Pharma AG Release: Interim Phase 2a Results For Spiegelmer® Olaptesed Pegol (NOX-A12) In CLL And MM Studies

  December 9, 2013

   · 

  1 min read
• Policy

  Baxter International, Inc. Files For Pediatric Indication Of RIXUBIS [Coagulation Factor IX (Recombinant)] Treatment For Hemophilia B In The United States

  December 9, 2013

   · 

  1 min read
• Drug Development

  Sunovion Pharmaceuticals Inc. Presents Positive Results From Two Phase 3 Studies Of Once-Daily Aptiom® (Eslicarbazepine Acetate) As Monotherapy Treatment For Partial-Onset Seizures

  December 9, 2013

   · 

  1 min read
• Drug Development

  Senesco Technologies, Inc. Announces Results Of Cohort 3 In SNS01-T Phase 1b/2a Trial

  December 9, 2013

   · 

  1 min read
• Sequenta, Inc.'s ClonoSIGHT MRD Test Can Detect Relapse Of Diffuse Large B-Cell Lymphoma More Than Seven Months Before CT Scan

  December 9, 2013

   · 

  1 min read
• First Analysis Of Extended Dosing With Celgene International Sárl Epigenetic Agent CC-486 In Patients With Higher-Risk Myelodysplastic Syndromes Presented At American Society of Hematology

  December 9, 2013

   · 

  1 min read
• Genetown

  Foundation Medicine, Inc. Release: FoundationOne™ Heme Enables Identification Of Genomic Alterations Not Identified By Conventional Methods Across Hematologic Malignancies

  December 9, 2013

   · 

  1 min read
• Genetown

  PHT Corporation Provides Web-Based Data Collection System For Eclinical Trials Via Apple Ipad®

  December 9, 2013

   · 

  1 min read
• Bio NC

  More Efficient Way To Grow Heart Muscle From Stem Cells Could Yield New Regenerative Therapies: AlphaMed

  December 9, 2013

   · 

  3 min read
• Drug Development

  Selecta Biosciences, Inc. Announces Successful Pre-Clinical Study Of SEL-201 As An Antigen-Specific Immune Tolerance Treatment For Patients Receiving Factor VIII Therapy

  December 9, 2013

   · 

  1 min read